Following this activity, participants should be able to: (1) Integrate recent advances and available clinical data to optimally select and sequence agents for the care of patients with HER2-negative metastatic breast cancer; (2) Select and sequence HER2-targeted agents in the first and subsequent lines of treatment of HER2-positive metastatic breast cancer; and (3) Discuss barriers to clinical trial access for patients with metastatic breast cancer and outline potential solutions.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/96386
- Start Date: 2025-01-21 06:00:00
- End Date: 2025-01-21 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AbbVie (Any division) - Amount: 0.0 - Is Kind Support: False Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Coherus BioSciences - Amount: 0.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 0.0 - Is Kind Support: False Source: Eisai, Inc. - Amount: 0.0 - Is Kind Support: False Source: Genentech (Any division) - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0.0 - Is Kind Support: False Source: Sanofi S.A. - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest